These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 23151915)

  • 21.
    Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Url C; Riechelmann H; Sprinzl GM; Thomé C; Treglia G; Kjaer A; Fraedrich G; Virgolini IJ
    Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients.
    Gabriel M; Andergassen U; Putzer D; Kroiss A; Waitz D; Von Guggenberg E; Kendler D; Virgolini IJ
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):92-9. PubMed ID: 20168291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.
    Kabasakal L; Demirci E; Ocak M; Decristoforo C; Araman A; Ozsoy Y; Uslu I; Kanmaz B
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1271-7. PubMed ID: 22526963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biodistribution and first clinical results of
    Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
    Velikyan I; Xu H; Nair M; Hall H
    Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study.
    Li S; Kurtaran A; Li M; Traub-Weidinger T; Kienast O; Schima W; Angelberger P; Virgolini I; Raderer M; Dudczak R
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1087-95. PubMed ID: 12768334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.
    Kroiss A; Putzer D; Frech A; Decristoforo C; Uprimny C; Gasser RW; Shulkin BL; Url C; Widmann G; Prommegger R; Sprinzl GM; Fraedrich G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1800-8. PubMed ID: 24072345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
    Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
    J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [
    Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Dekervel J; Van Cutsem E; Verslype C; Van Laere K; Bormans G; Deroose CM
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3033-3046. PubMed ID: 32617641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional imaging in neuroendocrine tumors: assessment of molecular heterogeneity using [
    Nogareda Seoane Z; Mallón Araújo MC; Calatayud Cubes A; Barberán Corral C; Domínguez Novoa Y; Cousillas Castiñeira A; Martínez Lago N; de Matías Leralta JM; Pubul Nuñez V
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(3):500011. PubMed ID: 38643835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.
    Kroiss A; Putzer D; Uprimny C; Decristoforo C; Gabriel M; Santner W; Kranewitter C; Warwitz B; Waitz D; Kendler D; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):865-73. PubMed ID: 21279352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vertebral metastases from neuroendocrine tumours: How to avoid false positives on
    Gauthé M; Testart Dardel N; Ruiz Santiago F; Ohnona J; Nataf V; Montravers F; Talbot JN
    Eur Radiol; 2018 Sep; 28(9):3943-3952. PubMed ID: 29532242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma.
    Schartinger VH; Dudás J; Decristoforo C; Url C; Schnabl J; Göbel G; Virgolini IJ; Riechelmann H; Rasse M; Waitz D; Putzer D
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1365-72. PubMed ID: 23685751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. (68)Ga-DOTA (0)-Tyr (3)-octreotide positron emission tomography in nasopharyngeal carcinoma.
    Schartinger VH; Dudás J; Url C; Reinold S; Virgolini IJ; Kroiss A; Riechelmann H; Uprimny C
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):20-4. PubMed ID: 25227762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Normal uptake of 68Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET.
    Jacobsson H; Larsson P; Jonsson C; Jussing E; Grybäck P
    Clin Nucl Med; 2012 Apr; 37(4):362-5. PubMed ID: 22391705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma.
    Hänscheid H; Sweeney RA; Flentje M; Buck AK; Löhr M; Samnick S; Kreissl M; Verburg FA
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1284-8. PubMed ID: 22526964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.